- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05259709
Eine Studie zur ImmunoPet-Bildgebung unter Verwendung von 89Zr-DFO-REGN5054 bei erwachsenen Teilnehmern mit soliden Krebserkrankungen, die mit Cemiplimab behandelt wurden
Eine First-in-Human-Studie zur 89Zr-DFO-REGN5054 (Anti-CD8)-Positronenemissionstomographie bei Patienten mit soliden Malignomen, die mit Cemiplimab behandelt wurden
This study is researching an experimental drug called 89Zr-DFO-REGN5054 and cemiplimab. The study is focused on patients with a type of cancer that can be potentially imaged using 89Zr-DFO-REGN5054 and show special tumor features that may be important to the way the immune system fights cancer.
The aim of the study is to study the safety and tolerability (how the body reacts to the drug) of the imaging agent 89Zr-DFO REGN5054.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drugs
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects)
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Groningen, Niederlande, 9700 RB
- UMC Groningen
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
- Advanced or metastatic solid tumors that may respond to anti-programmed cell death 1 (PD-1) immunotherapy
- Measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
- Adequate organ and bone marrow function as defined in the protocol
- Willing and able to comply with clinic visits and study-related procedures (including required tumor biopsy for Part B)
Key Exclusion Criteria:
- Currently receiving another cancer treatment or inadequate time since last therapy, as defined in the protocol
- Has not yet recovered from acute toxicities from prior therapy; exceptions defined in the protocol
- Prior treatment with a blocker of the PD-1/Programmed death ligand 1 (PD-L1) pathway
- Currently receiving or has received chimeric antigen receptor (CAR-T) cell therapy
- Symptomatic or untreated brain metastases, leptomeningeal disease, or spinal cord compression
- Known history of or any evidence of interstitial lung disease, active, noninfectious pneumonitis (past 5 years) or active tuberculosis
NOTE: Other protocol defined inclusion/exclusion criteria apply.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Single ascending dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab
Part A: Doses of 89Zr˗DFO˗REGN5054 may be reduced based upon assessment. |
Administered by intravenous (IV) infusion during Part A and B. Administered by IV infusion every 3 weeks (Q3W).
Andere Namen:
|
|
Experimental: Defined dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab
Part B: Defined dose of 89Zr˗DFO˗REGN5054 determined in Part A. |
Administered by intravenous (IV) infusion during Part A and B. Administered by IV infusion every 3 weeks (Q3W).
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence and severity of treatment-emergent adverse events (TEAEs)
Zeitfenster: Up to day 8, after the infusion of 89Zr˗DFO˗REGN5054
|
Part A |
Up to day 8, after the infusion of 89Zr˗DFO˗REGN5054
|
|
Incidence and severity of TEAEs
Zeitfenster: Up to approximately week 115
|
Part A and B |
Up to approximately week 115
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Clinical dosimetry based on tissue radiation absorbed dose calculated from positron emission tomography (PET) image acquisition data
Zeitfenster: On days 1, 5 and 8
|
After injection of 37 megabecquerel (MBq) of 89Zr-DFO-REGN5054, a series of whole-body positron emission tomography (PET) images will be obtained over a period of up to 8 days and corrected for attenuation by low-dose computed tomography (CT) scans using PET/CT. The radiation effective dose per organ/tissue will be calculated for each organ using Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA/EXM). The unit of effective dose per organ/tissue will be millisievert per Minimum Base Quantity (MBq) for each participant's organ/tissue. The final values for each organ will be averaged across participants for each mass dose |
On days 1, 5 and 8
|
|
Clinical dosimetry based on tissue radiation effective dose calculated from PET image acquisition data
Zeitfenster: On days 1, 5 and 8
|
After injection of 37 MBq of 89Zr-DFO-REGN5054, a series of whole-body PET images will be obtained over a period of up to 8 days and corrected for attenuation by low-dose CT scans using PET/CT. The radiation effective dose for the whole body will be calculated using OLINDA/EXM software. The unit of effective dose will be millisievert per MBq for the whole body for each participant. The final values will be averaged across participants for each mass dose. |
On days 1, 5 and 8
|
|
Concentration of 89Zr-DFO-REGN5054 in serum
Zeitfenster: On days 1, 5 and 8
|
Part A |
On days 1, 5 and 8
|
|
Serum imaging agent activity concentration of area under the curve (AUC0-7)
Zeitfenster: Up to day 8
|
Part A |
Up to day 8
|
|
89Zr-DFO-REGN5054 uptake across cluster of differentiation 8 (CD8)-expressing normal tissues and tumors
Zeitfenster: At the time of imaging, up to day 8
|
Part A and Part B |
At the time of imaging, up to day 8
|
|
Blood pool uptake of 89Zr-DFO-REGN5054 with subsequent calculation of standardized uptake value (SUV) tumor-to-blood ratios
Zeitfenster: At the time of imaging, up to day 8
|
Part A and Part B |
At the time of imaging, up to day 8
|
|
Association of 89Zr˗DFO˗REGN5054 autoradiographic signal intensity distribution with CD8 expression in tumor tissues
Zeitfenster: At Baseline
|
Part A and Part B |
At Baseline
|
|
Association of 89Zr-DFO-REGN5054 uptake with CD8 expression in tumor tissues
Zeitfenster: At Baseline
|
Part B |
At Baseline
|
|
Association of tumor-to-blood ratio of 89Zr-DFO-REGN5054 with CD8 expression in tumor tissues
Zeitfenster: At Baseline
|
Part B |
At Baseline
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Clinical Trials Management, Regeneron Pharmaceuticals
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- R5054-ONC-1843
- 2019-001604-38 (EudraCT-Nummer)
- 2019 (US NIH Stipendium/Vertrag)
- 2024-515351-37-00 (Ctis)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD-Sharing-Zeitrahmen
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-Sharing-Zugriffskriterien
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
- ANALYTIC_CODE
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .